| HOME >> BIOLOGY >> TECHNOLOGY |
WORCESTER, Mass. and TORONTO, May 3, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced publication of results of studies applicable to the early diagnosis, and possibly treatment of, Type 1 diabetes. The study, entitled: "Recognition of Ii-Key/MHC Class II Epitope Hybrids Derived from Proinsulin and GAD Peptides by T Cells in Type 1 Diabetes" appears in the April issue of the international peer-reviewed journal Hormone and Metabolism Research. The article reports on the results of a collaborative study between scientists in the laboratory of Professor Paolo Pozzilli at the University Campus Bio-Medico in Rome, Italy and scientists at Generex's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).
(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)
The methodology reported in the publication for identification of autoimmune cells in diabetic patients relies upon the Ii-Key technology developed at Antigen Express. Specifically, attaching the Ii-Key segment to an antigenic peptide designed to activate CD4+ T helper cells increases the potency of the peptide while not altering its specificity. To date, this technology has been used successfully to increase the potency of a variety of antigenic peptides. The most advanced Ii-Key modified peptide clinically is a HER2 peptide that is currently in a Phase II clinical trial as an immunotherapeutic vaccine for patients with breast cancer.
In the case of Type 1 diabetes, autoimmunity is directed at insulin producing cells in the pancreas; in particular, towards the proinsulin and glutamic acid decarboxylase (GAD65) proteins. The study reports that Ii-Key modified peptides from each of these proteins were ca
'/>"/>
| SOURCE Generex Biotechnology Corporation Copyright©2010 PR Newswire. All rights reserved |